[go: up one dir, main page]

CA2102447A1 - Cyclopeptides - Google Patents

Cyclopeptides

Info

Publication number
CA2102447A1
CA2102447A1 CA002102447A CA2102447A CA2102447A1 CA 2102447 A1 CA2102447 A1 CA 2102447A1 CA 002102447 A CA002102447 A CA 002102447A CA 2102447 A CA2102447 A CA 2102447A CA 2102447 A1 CA2102447 A1 CA 2102447A1
Authority
CA
Canada
Prior art keywords
asp
gly
arg
ala
cyclopeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002102447A
Other languages
French (fr)
Other versions
CA2102447C (en
Inventor
Alfred Jonczyk
Gunter Holzemann
Brunhilde Felding-Habermann
Friedrich Rippmann
Guido Melzer
Beate Diefenbach
Horst Kessler
Roland Haubner
Jochen Wermuth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2102447A1 publication Critical patent/CA2102447A1/en
Application granted granted Critical
Publication of CA2102447C publication Critical patent/CA2102447C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to novel cyclopeptides of the formula I cyclo-(A-B-C-D-Arg) I in which A and B are each independently of one another Ala, Asn, Asp, Arg, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val, C is Asp or Asp (O-C1-4-alkyl) and D is Gly or Ala, at least two of the amino acid radicals stated being present in the D-form, and their salts. These compounds act as integrin inhibitors and can be used in particular for the prophylaxis and treatment of disorders of the circulation and in tumour therapy.
CA002102447A 1992-11-06 1993-11-04 Cyclopeptides Expired - Lifetime CA2102447C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4237456.1 1992-11-06
DE4237456A DE4237456A1 (en) 1992-11-06 1992-11-06 cyclopeptides

Publications (2)

Publication Number Publication Date
CA2102447A1 true CA2102447A1 (en) 1994-05-07
CA2102447C CA2102447C (en) 2007-04-10

Family

ID=6472232

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002102447A Expired - Lifetime CA2102447C (en) 1992-11-06 1993-11-04 Cyclopeptides

Country Status (21)

Country Link
EP (1) EP0596350B1 (en)
JP (1) JP3681764B2 (en)
KR (1) KR100238894B1 (en)
CN (1) CN1038751C (en)
AT (1) ATE154037T1 (en)
AU (1) AU666586B2 (en)
CA (1) CA2102447C (en)
CZ (1) CZ286170B6 (en)
DE (2) DE4237456A1 (en)
DK (1) DK0596350T3 (en)
ES (1) ES2105041T3 (en)
GR (1) GR3024550T3 (en)
HU (1) HU215600B (en)
MX (1) MX9306885A (en)
NO (1) NO309864B1 (en)
PL (1) PL177772B1 (en)
RU (1) RU2129563C1 (en)
SK (1) SK280597B6 (en)
TW (1) TW340849B (en)
UA (1) UA43822C2 (en)
ZA (1) ZA938281B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4237456A1 (en) * 1992-11-06 1994-05-11 Merck Patent Gmbh cyclopeptides
DE4310643A1 (en) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclic adhesion inhibitors
DE19538741A1 (en) * 1995-10-18 1997-04-24 Merck Patent Gmbh Cyclopeptide derivatives
DE19653036A1 (en) * 1996-12-19 1998-06-25 Merck Patent Gmbh Cyclopeptide derivatives
RU2255765C2 (en) * 2000-01-21 2005-07-10 Чилдренз Хоспитал Лос-Анджелес Method for inhibiting cerebral tumors growth due to selected antagonists of integrins
CZ2003584A3 (en) * 2000-08-30 2003-08-13 F. Hoffmann-La Roche Ag Selective cyclic peptides
FR2814744B1 (en) * 2000-10-04 2002-11-29 Commissariat Energie Atomique CYCLOPEPTIDES, THEIR PREPARATION PROCESS AND THEIR USE AS ANGIOGENESIS INHIBITOR OR ACTIVATOR
WO2019098811A2 (en) * 2017-11-20 2019-05-23 주식회사 노브메타파마 Composition for preventing, alleviating, or treating bone loss diseases, comprising cyclo(his-pro) (chp)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU892871A1 (en) * 1980-07-28 1983-09-15 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвсср Cyclic analog of bradiquinine having prolonged hypotensive effect
US4816449A (en) * 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents
GB8729802D0 (en) * 1987-12-22 1988-02-03 Beecham Group Plc Novel compounds
DE4237456A1 (en) * 1992-11-06 1994-05-11 Merck Patent Gmbh cyclopeptides
US5516889A (en) * 1993-06-21 1996-05-14 University Technologies International, Inc. Synthetic thrombin receptor peptides

Also Published As

Publication number Publication date
CN1093090A (en) 1994-10-05
PL177772B1 (en) 2000-01-31
NO934003L (en) 1994-05-09
DE59306654D1 (en) 1997-07-10
DK0596350T3 (en) 1997-12-29
CZ286170B6 (en) 2000-02-16
CN1038751C (en) 1998-06-17
JPH0892282A (en) 1996-04-09
UA43822C2 (en) 2002-01-15
GR3024550T3 (en) 1997-12-31
KR940011479A (en) 1994-06-21
DE4237456A1 (en) 1994-05-11
HUT68321A (en) 1995-06-28
CZ235293A3 (en) 1994-07-13
TW340849B (en) 1998-09-21
CA2102447C (en) 2007-04-10
MX9306885A (en) 1995-01-31
ZA938281B (en) 1994-06-07
KR100238894B1 (en) 2000-01-15
ATE154037T1 (en) 1997-06-15
HU215600B (en) 1999-01-28
SK121793A3 (en) 1995-06-07
RU2129563C1 (en) 1999-04-27
PL300935A1 (en) 1994-05-16
EP0596350A1 (en) 1994-05-11
EP0596350B1 (en) 1997-06-04
AU5039993A (en) 1994-05-19
ES2105041T3 (en) 1997-10-16
JP3681764B2 (en) 2005-08-10
NO934003D0 (en) 1993-11-05
AU666586B2 (en) 1996-02-15
SK280597B6 (en) 2000-04-10
NO309864B1 (en) 2001-04-09

Similar Documents

Publication Publication Date Title
NZ248377A (en) Use of interleukin-1 beta protease and interleukin-1 beta protease inhibitors
IL104314A0 (en) Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
CA2148194A1 (en) Cyclopeptides of the formula i
CA2143610A1 (en) Use of norastemizole for the treatment of allergic disorders
CA2102447A1 (en) Cyclopeptides
CA2002924A1 (en) Anti-Thrombins
ZA921270B (en) Peptides for treatment
NO941151L (en) Linear adhesion inhibitors
AU8005201A (en) Pharmaceutical composition comprising an analgesic peptide
CA2102606A1 (en) Compositions for the treatment of chronic fatigue syndrome
CA2096933A1 (en) Compounds and compositions which inhibit bone resorption
DE3569541D1 (en) Pharmacologically active peptides
RU93050068A (en) CYCLOPEPTIDES, METHOD OF THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS AND METHOD OF THEIR PRODUCTION, METHOD OF TREATMENT
AU586647B2 (en) Improvements in or relating to peptides that inhibit renin
CA2290739A1 (en) New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy
YU48997A (en) Novel biologically active proteins, their pharmaceutical compositions and procedure for obtaining thereof
EP0613375A4 (en) Pharmaceutical lysine-containing polypeptide compositions and methods of use thereof.
RU95120588A (en) CYCLOGEXAEPEPTIDES, THEIR MIXTURES, METHOD FOR PRODUCING AND USING THEM
EP0248231A3 (en) Pharmacologically active peptides
NZ268039A (en) Use of efaroxan in treating parkinson's disease
KR950704358A (en) Cathepsin L specific inhibitory polypeptide
IL115825A0 (en) Therapeutic protein
EP0621789A4 (en) Pharmaceutical pentapeptide compositions and methods of use thereof.
RU94036002A (en) Protease inhibitor, dna, vector, cell, method of inhibitor preparing, pharmaceutical composition

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20131104